Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-frequency intravenous tocilizumab in pediatric systemic juvenile idiopathic arthritis with prior resolved laboratory abnormalities
MOH_2017-04-23_000329Phase 4Recruiting
- Sponsor
- Roche
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of tocilizumab in systemic juvenile idiopathic arthritis (SJIA) (2 arms), sponsored by Roche. Started Jun 2016; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on MOH_2017-04-23_000329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-23_000329.